Designates July 17, 2024, as “Glioblastoma Awareness Day.”
Acknowledges approximately 14,490 new cases of glioblastoma diagnosed in the United States in 2023.
Describes glioblastoma as the most common, aggressive, and deadly type of brain tumor.
Notes the 5-year survival rate for glioblastoma patients is only 6.9 percent, with a median survival time of 8 months.
Highlights the significant challenges in treating glioblastoma due to the brain’s complexity.
Emphasizes the critical role of patients and caregivers in advancing research for glioblastoma.
Points out the high out-of-pocket costs for brain cancer patients, especially during initial and end-of-life care phases.
Mentions the lack of screening or early detection methods for glioblastoma and the obstacles to developing new treatments.
References the World Health Organization’s 2021 reclassification of brain tumors, including changes to glioblastoma diagnosis criteria.
Notes that since the 1920s, only 5 drugs and 1 medical device have been FDA-approved specifically for glioblastoma treatment, with little change in mortality rates over the past 30 years.
Mentions the establishment of the Glioblastoma Therapeutics Network by the National Cancer Institute in 2020 to support the development of therapies.
Calls for greater public awareness of glioblastoma, highlighting the urgent medical needs of patients and opportunities for research and treatment advances.
Encourages increased public awareness and honors those affected by glioblastoma.
Supports efforts to develop better treatments to improve prognosis and quality of life for those diagnosed.
Recognizes the importance of molecular biomarker testing in diagnosing and treating glioblastoma.
Expresses support for individuals battling brain tumors and their support networks.
Urges collaborative research approaches among governmental, private, and nonprofit organizations.
Encourages continued investment in glioblastoma research and treatments, including through the Glioblastoma Therapeutics Network.
